Adachi Masashi, Hinatsu Yuta, Kusamori Kosuke, Katsumi Hidemasa, Sakane Toshiyasu, Nakatani Manabu, Wada Koichi, Yamamoto Akira
Department of Biopharmaceutics, Kyoto Pharmaceutical University, 5, Misasagi-Nakauchicho, Yamashina-ku, Kyoto 607-8414, Japan; Department of Chemistry, Manufacturing, and Control, Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Ltd., 6-7-5, Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.
Department of Biopharmaceutics, Kyoto Pharmaceutical University, 5, Misasagi-Nakauchicho, Yamashina-ku, Kyoto 607-8414, Japan.
Eur J Pharm Sci. 2015 Aug 30;76:225-30. doi: 10.1016/j.ejps.2015.05.015. Epub 2015 May 16.
Formulation development of poorly water-soluble compounds can be challenging because of incomplete dissolution that causes low and variable bioavailability. Enhancing compound solubility is important and many techniques have been investigated to that end, but they require specific materials and machinery. This study investigates the incorporation of a pH-modifier as a method to increase compound solubility and uses ketoconazole (KZ), which is weakly basic (pKa: 6.5), as a model compound. Organic acids are effective pH-modifiers and are generally used in pharmaceutical industries. We successfully obtained granules containing variable organic acids (KZ/acid granule) using a high-shear mixer. Dissolution tests of the KZ/acid granule resulted in highly enhanced solubility under non-sink conditions. Adding water-soluble acids, such as citric acid (CA) and tartaric acid, resulted in more than 8-fold higher dissolution at pH 6.0 compared to that of KZ only. The granules containing citric acid (KZ/CA granule) improved the dissolution of KZ after oral administration to rats under low gastric acid conditions, where the bioavailability of the KZ/CA granules at elevated gastric pH was comparable with that of KZ only at gastric acidic pH. The incorporation of organic acids would result in effective therapeutic outcomes independent of gastric pH in patients. In addition, higher bioavailability of KZ was observed after oral administration of KZ/CA granules under gastric acidic pH conditions than that of KZ alone. Thus, CA improved the dissolution and absorption rate of KZ after oral administration.
由于不完全溶解会导致低且可变的生物利用度,难溶性化合物的制剂开发具有挑战性。提高化合物的溶解度很重要,为此人们研究了许多技术,但这些技术需要特定的材料和机械。本研究考察了加入pH调节剂作为提高化合物溶解度的一种方法,并使用弱碱性的酮康唑(KZ,pKa:6.5)作为模型化合物。有机酸是有效的pH调节剂,通常用于制药行业。我们使用高剪切混合器成功制备了含有不同有机酸的颗粒(KZ/酸颗粒)。KZ/酸颗粒的溶出试验结果表明,在非漏槽条件下其溶解度显著提高。加入水溶性酸,如柠檬酸(CA)和酒石酸,在pH 6.0时的溶出度比仅含KZ时高出8倍以上。含柠檬酸的颗粒(KZ/CA颗粒)在大鼠胃酸较低的条件下口服给药后提高了KZ的溶出度,在胃pH升高时KZ/CA颗粒的生物利用度与胃酸pH时仅含KZ的生物利用度相当。加入有机酸将在患者中产生与胃pH无关的有效治疗效果。此外,在胃酸pH条件下口服KZ/CA颗粒后,观察到KZ的生物利用度高于单独使用KZ时。因此,CA提高了KZ口服给药后的溶出度和吸收速率。